Skip to main content

Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody.

Publication ,  Journal Article
Heydarchi, B; Fong, DS; Gao, H; Salazar-Quiroz, NA; Edwards, JM; Gonelli, CA; Grimley, S; Aktepe, TE; Mackenzie, C; Wales, WJ; van Gils, MJ ...
Published in: Cell Rep Med
May 17, 2022

Human immunodeficiency virus type 1 (HIV-1) vaccination of cows has elicited broadly neutralizing antibodies (bNAbs). In this study, monoclonal antibodies (mAbs) are isolated from a clade A (KNH1144 and BG505) vaccinated cow using a heterologous clade B antigen (AD8). CD4 binding site (CD4bs) bNAb (MEL-1872) is more potent than a majority of CD4bs bNAbs isolated so far. MEL-1872 mAb with CDRH3 of 57 amino acids shows more potency (geometric mean half-maximal inhibitory concentration [IC50]: 0.009 μg/mL; breadth: 66%) than VRC01 against clade B viruses (29-fold) and than CHO1-31 against tested clade A viruses (21-fold). It also shows more breadth and potency than NC-Cow1, the only other reported anti-HIV-1 bovine bNAb, which has 60% breadth with geometric mean IC50 of 0.090 μg/mL in this study. Using successive different stable-structured SOSIP trimers in bovines can elicit bNAbs focusing on epitopes ubiquitous across subtypes. Furthermore, the cross-clade selection strategy also results in ultra-potent bNAbs.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cell Rep Med

DOI

EISSN

2666-3791

Publication Date

May 17, 2022

Volume

3

Issue

5

Start / End Page

100635

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Vaccines
  • HIV-1
  • HIV Infections
  • HIV Antibodies
  • Female
  • Cattle
  • CD4 Antigens
  • Broadly Neutralizing Antibodies
  • Binding Sites
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Heydarchi, B., Fong, D. S., Gao, H., Salazar-Quiroz, N. A., Edwards, J. M., Gonelli, C. A., … Purcell, D. F. J. (2022). Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. Cell Rep Med, 3(5), 100635. https://doi.org/10.1016/j.xcrm.2022.100635
Heydarchi, Behnaz, Danielle S. Fong, Hongmei Gao, Natalia A. Salazar-Quiroz, Jack M. Edwards, Christopher A. Gonelli, Samantha Grimley, et al. “Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody.Cell Rep Med 3, no. 5 (May 17, 2022): 100635. https://doi.org/10.1016/j.xcrm.2022.100635.
Heydarchi B, Fong DS, Gao H, Salazar-Quiroz NA, Edwards JM, Gonelli CA, et al. Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. Cell Rep Med. 2022 May 17;3(5):100635.
Heydarchi, Behnaz, et al. “Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody.Cell Rep Med, vol. 3, no. 5, May 2022, p. 100635. Pubmed, doi:10.1016/j.xcrm.2022.100635.
Heydarchi B, Fong DS, Gao H, Salazar-Quiroz NA, Edwards JM, Gonelli CA, Grimley S, Aktepe TE, Mackenzie C, Wales WJ, van Gils MJ, Cupo A, Rouiller I, Gooley PR, Moore JP, Sanders RW, Montefiori D, Sethi A, Purcell DFJ. Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. Cell Rep Med. 2022 May 17;3(5):100635.

Published In

Cell Rep Med

DOI

EISSN

2666-3791

Publication Date

May 17, 2022

Volume

3

Issue

5

Start / End Page

100635

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Vaccines
  • HIV-1
  • HIV Infections
  • HIV Antibodies
  • Female
  • Cattle
  • CD4 Antigens
  • Broadly Neutralizing Antibodies
  • Binding Sites